DEA’s suspension of McKesson Corporation Retraction

Posted in Latest News on January 19, 2017.

The previous post, regarding the DEA’s suspension of McKesson Corporation’s sales of controlled substances from distribution in Florida, was found to be confusing. This suspension will impact one distribution center in Florida and impacts only the handling of hydromorphone. The Florida Department of Health and Division of Medical Quality Assurance apologizes for any confusion that may have resulted from that message. For specific details about McKesson’s agreement with the DEA, please contact the DEA. For questions about the potential impact of the sanctions in Florida, please contact the DOH’s Medical Quality Assurance.



More Latest News

Meningococcal Disease and Vaccines
April 14, 2022

The Florida Department of Health (FDOH) is responding to an outbreak of meningococcal disease in some areas of Florida. Continue reading


Second Quarter Performance Report
April 12, 2022

Released for the
2021 – 2022 Fiscal Year Continue reading